Kythera Biopharmaceuticals announced on Monday the approval of an injection to improve the appearance of a double chin by an FDA Advisory Committee.

According to a press release posted to the company website, the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee approved ATX-101 by a unanimous 17-0 vote. If approved by the FDA itself, the drug would be a “first-in-class submental contouring injectable drug,” the company notes.

“We are pleased that the FDA advisory committee recognized the importance of providing patients with a clinically-proven treatment option specifically developed to contour submental fullness, a much-cited yet undertreated facial aesthetic complaint,” Kythera’s Chief Medical Officer Frederick Beddingfield said in a statement.

Read more

The Emergency Election Sale is now live! Get 30% to 60% off our most popular products today!

Related Articles